Drugs / DNA CON-S env
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03505060 | Jan → May 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 1 | NCT02296541 | Dec 2014 → Nov 2016 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNA CON-S env | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03505060 ↗ |
| Modality | Vaccine | “HIV DNA CON-S Env Vaccine” NCT03505060 ↗ |
| Route | Intramuscular | “4 mg to be administered as 1 mL IM” NCT02296541 ↗ |